Skip to main content

Branded

  • FDA approves Mekinist in combination with Tafinlar to treat patients with advanced melanoma

    NEW YORK — The Food and Drug Administration recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (i.e., cannot be removed by surgery) or metastatic (i.e., late-stage), Onco360 announced last week. 

    Both Mekinist and Tafinlar are only available in limited distribution, and Onco360 is one of the few pharmacies with access to both medications.

  • CHPA responds to Food and Drug Administration’s APAP recommendation

    WASHINGTON — The Consumer Healthcare Products Association on Thursday responded to the Food and Drug Administration’s recommendation to discontinue prescribing and dispensing prescription combination medicines that contain more than 325 mg of acetaminophen per dosage unit, suggesting it would not impact use of over-the-counter formulations containing acetaminophen.

  • Nuvo Research's Pennsaid 2% approved to treat pain associated with osteoarthritis of the knee

    MISSISSAUGA, Ontario — Nuvo Research on Friday announced that the U.S. Food and Drug Administration approved Mallinckrodt's new drug application for Pennsaid (diclofenac sodium topical solution) 2%.

  • NCPA places support behind Diabetic Testing Supply Access Act

    ALEXANDRIA, Va. — The National Community Pharmacists Association on Thursday expressed its support behind the Diabetic Testing Supply Access Act (S. 1935). 

    The legislation would allow independent community pharmacies to provide same-day delivery of diabetes testing supplies to Medicare beneficiaries and was introduced by Senss Jerry Moran, R-Kan., and John Thune, R-S.D. 

    Since July 1, 2013 community pharmacies have been banned from delivering DTS to beneficiaries, including those who are homebound or in long-term care or assisted living facilities. 

  • National Consumers League survey finds 1-in-5 adults never received a flu shot

    WASHINGTON — A survey released by the National Consumers League found that more than 1-in-5 (22%) U.S. parents surveyed admitted they’ve never received a flu shot, and only half (53%) of parents with children ages 17 years and younger have received a flu vaccination within the last year. 

  • NCPA: Preferred pharmacy networks don't necessarily net prescription savings

    ALEXANDRIA, Va. — The Medicare Part D program and taxpayers often pay more when prescription drugs are obtained through "preferred" pharmacies and mail order than they would if the same prescriptions were filled through other, "non-preferred" pharmacies, according to a cost comparison made by the National Community Pharmacists Association released Thursday using the Medicare Plan Finder website. The findings come shortly after recently proposed requirements that officials with the U.S.

  • Par Pharmaceutical to distribute authorized generic of Covis's Lanoxin (digoxin) tablets

    WOODCLIFF LAKE, N.J. — Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets. 

    According to IMS Health data, annual U.S. sales of digoxin tablets are approximately $44 million. 

  • FDA advisory panel recommends approval of Merck's vorapaxar

    WHITEHOUSE STATION, N.J. — Merck on Wednesday commended the U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation for approval of vorapaxar. Vorapaxar is the company’s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack.

X
This ad will auto-close in 10 seconds